Biosimilars in paediatric inflammatory bowel disease

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 24, Issue 35

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

1034

HTML

3332

Tables (1-4)

164

Sum=4530

Publishing Process of This Article

Item

Count

Browse

1046

Download

950

Sum=1996

Sep 21, 2018 (publication date) through May 6, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Gastroenterol. Sep 21, 2018; 24(35): 4021-4027
Published online Sep 21, 2018. doi: 10.3748/wjg.v24.i35.4021

Table 3 Biosimilars approved by the European Medicinal Agency in use among inflammatory bowel disease patients[38-40]

Citation: Sieczkowska-Golub J, Jarzebicka D, Oracz G, Kierkus J. Biosimilars in paediatric inflammatory bowel disease. World J Gastroenterol 2018; 24(35): 4021-4027
URL: https://www.wjgnet.com/1007-9327/full/v24/i35/4021.htm
DOI: https://dx.doi.org/10.3748/wjg.v24.i35.4021